Marizyme, Inc.
MRZM · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.14 | -0.04 |
| FCF Yield | -103.02% | -50.28% | -9.07% | -5.11% |
| EV / EBITDA | -0.45 | -0.77 | -5.68 | -12.36 |
| Quality | ||||
| ROIC | -186.37% | -34.76% | -13.94% | -12.38% |
| Gross Margin | 36.99% | 76.74% | 61.79% | 70.43% |
| Cash Conversion Ratio | 0.07 | 0.28 | 0.53 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 45.36% | 5.80% | – | 113.75% |
| Free Cash Flow Growth | 56.83% | -87.52% | -71.60% | -2,597.69% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | -0.14 | 0.21 | 0.30 |
| Interest Coverage | -1.13 | -4.65 | -70.00 | -127.60 |
| Efficiency | ||||
| Inventory Turnover | 16.37 | 0.25 | 3.59 | 1.03 |
| Cash Conversion Cycle | -1,911.55 | -6,618.69 | -6,470.27 | -1,612.29 |